Drug combinations useful for prevention of restenosis
CA 2408606 A1 · Owner: Kopia, Gregory A. · Inventors: Falotico, Robert F.; Kopia, Gregory A.; Llanos, Gerald H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin vincristine or taxol , is administered in combination with the antiinflammatory agent dexamethasone, to patients systemically either subcutaneously or intravenously. In another embodiment of the invention, the antiproliferative and antiinflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 25, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 25, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 25, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.